The signal pathways and treatment of cytokine storm in COVID-19

L Yang, X **e, Z Tu, J Fu, D Xu, Y Zhou - Signal transduction and …, 2021 - nature.com
Abstract The Coronavirus Disease 2019 (COVID-19) pandemic has become a global crisis
and is more devastating than any other previous infectious disease. It has affected a …

Therapeutic advances in COVID-19

N Murakami, R Hayden, T Hills, H Al-Samkari… - Nature Reviews …, 2023 - nature.com
Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed
millions of lives. Unlike the early days of the pandemic, when management decisions were …

Target trial emulation: a framework for causal inference from observational data

MA Hernán, W Wang, DE Leaf - Jama, 2022 - jamanetwork.com
Quantifying the effect of a treatment on a clinical outcome—causal inference—requires the
comparison of outcomes under different courses of action. For example, to quantify the effect …

Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission …

CKH Wong, ICH Au, KTK Lau, EHY Lau… - The Lancet Infectious …, 2022 - thelancet.com
Background Data on the effectiveness of oral antivirals in patients with mild-to-moderate
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the …

The genomic landscape of 2,023 colorectal cancers

AJ Cornish, AJ Gruber, B Kinnersley, D Chubb… - Nature, 2024 - nature.com
Colorectal carcinoma (CRC) is a common cause of mortality, but a comprehensive
description of its genomic landscape is lacking,,,,,,–. Here we perform whole-genome …

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

VC Veiga, JAGG Prats, DLC Farias, RG Rosa… - bmj, 2021 - bmj.com
Objective To determine whether tocilizumab improves clinical outcomes for patients with
severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open label trial …

Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic

KKW To, S Sridhar, KHY Chiu, DLL Hung… - Emerging microbes & …, 2021 - Taylor & Francis
Without modern medical management and vaccines, the severity of the Coronavirus
Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome (SARS) …

Tocilizumab in patients hospitalized with Covid-19 pneumonia

C Salama, J Han, L Yau, WG Reiss… - … England Journal of …, 2021 - Mass Medical Soc
Abstract Background Coronavirus disease 2019 (Covid-19) pneumonia is often associated
with hyperinflammation. Despite the disproportionate incidence of Covid-19 among …

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

FX Lescure, H Honda, RA Fowler, JS Lazar… - The Lancet …, 2021 - thelancet.com
Background Elevated proinflammatory cytokines are associated with greater COVID-19
severity. We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor …

Dysbiosis of human gut microbiome in young-onset colorectal cancer

Y Yang, L Du, D Shi, C Kong, J Liu, G Liu, X Li… - Nature …, 2021 - nature.com
The incidence of sporadic young-onset colorectal cancer (yCRC) is increasing. A significant
knowledge gap exists in the gut microbiota and its diagnostic value for yCRC patients …